Brachytherapy Treatment Planning System Research Articles

The Effect of Computed Tomography-Guided125I Radioactive Particle Implantation in Treating Cancer and Its Pain

Pain is a prevalent and serious problem in patients with cancer. This study aimed to investigate the clinical value of the implantation of radioactive particle 125I in treating cancer and its pain. From February 2014 to February 2015, 38 patients with malignant tumor received computed tomography (CT)-guided 125I radioactive particle implantation to treat cancer pain in this hospital. Before surgery, the lesions were calculated by brachytherapy treatment planning system (TPS) to get the local number of particles that are required for implantation. For a period after implantation, TPS was used again to assess the effect of treatment. The 38 patients received 6-month follow-up, and the CT scan was used to evaluate the local tumor. The visual analogue scale (VAS) was used to assess the pain. The curative effect was evaluated at postoperative 2, 4, and 6 months, and the curative effect was 34.2%, 73.68%, and 89.47%, respectively. The preoperative VAS score of the 38 patients was 5.48 ± 2.50 (13 cases of mild pain, 19 cases of moderate pain, and 6 cases of severe pain), and their pain was improved in different degrees after operation. CT-guided 125I radioactive particle implantation is a safe and effective treatment for cancer and its pain.

Effect of image fusion technology of radioactive particles implantation before and after the planning target and dosimetry

Objective: To compare the post-implant target volumes and dosimetric evaluation with pre-plan, the gross tumor volume(GTV) by CT image fusion-based and the manual delineation of target volume in CT guided radioactive seeds implantation. Methods: A total of 10 patients treated under CT-guidance (125)I seed implantation during March 2016 to April 2016 were analyzed in Peking University Third Hospital.All patients underwent pre-operative CT simulation, pre-operative planning, implantation seeds, CT scanning after seed implantation and dosimetric evaluation of GTV.In every patient, post-implant target volumes were delineated by both two methods, and were divided into two groups. Group 1: image fusion pre-implantation simulation and post-operative CT image, then the contours of GTV were automatically performed by brachytherapy treatment planning system; Group 2: the contouring of the GTV on post-operative CT image were performed manually by three senior radiation oncologists independently. The average of three data was sets. Statistical analyses were performed using SPSS software, version 3.2.0. The paired t-test was used to compare the target volumes and D(90) parameters in two modality. Results: In Group 1, average volume of GTV in post-operation group was 12-167(73±56) cm(3). D(90) was 101-153 (142±19)Gy. In Group 2, they were 14-186(80±58)cm(3) and 96-146(122±16) Gy respectively. In both target volumes and D(90), there was no statistical difference between pre-operation and post-operation in Group 1.The D(90) was slightly lower than that of pre-plan group, but there was no statistical difference (P=0.142); in Group 2, between pre-operation and post-operation group, there was a significant statistical difference in the GTV (P=0.002). The difference of D(90) was similarly (P<0.01). Conclusion: The method of delineation of post-implant GTV through fusion pre-implantation simulation and post-operative CT scan images, the contours of GTV are automatically performed by brachytherapy treatment planning system appears to have improved more accuracy, reproducibility and convenience than manual delineation of target volume by maximum reduce the interference from artificial factor and metal artifacts. Further work and more cases are required in the future.

Design and validation of a CT-guided robotic system for lung cancer brachytherapy.

Currently, lung brachytherapy in clinical setting is a complex procedure. Operation accuracy depends on accurate positioning of the template; however, it is difficult to guarantee the positioning accuracy manually. Application of robotic-assisted systems can simplify the procedure and improve the manual positioning accuracy. Therefore, a novel CT-guided robotic system was developed to assist the lung cancer brachytherapy. A four degree-of-freedom (DOF) robot, controlled by a lung brachytherapy treatment planning system (TPS) software, was designed and manufactured to assist the template positioning. Target position of the template can be obtained from the treatment plan, thus the robot is driven to the target position automatically. The robotic system was validated in both the laboratory and the CT environment. In laboratory environment, a 3D laser tracker and an inertial measurement unit (IMU) were used to measure the mechanical accuracy in air, which includes positioning accuracy and position repeatability. Working reliability was also validated in this procedure by observing the response reliability and calculating the position repeatability. Imaging artifacts and accuracy of the robot registration were validated in the CT environment by using an artificial phantom with fiducial markers. CT images were obtained and used to test the image artifact and calculate the registration accuracy. Phantom experiments were conducted to test the accuracy of needle insertion by using a transparent hydrogel phantom with a high imitation artificial phantom. Also, the efficiency was validated in this procedure by comparing time costs in manual positioning with robotic positioning under the same experimental conditions. The robotic system achieved the positioning accuracy of 0.28 ± 0.25 mm and the position repeatability of 0.09 ± 0.11 mm. Experimental results showed that the robot was CT-compatible and responded reliably to the control commands. The mean registration accuracy of the robotic system was 0.49 ± 0.29 mm. Phantom experiments indicated that the accuracy of needle insertion was 1.5 ± 1.7 mm at a depth ranging from 30 to 80 mm. The time used to adjust the template to the target position was 12 min on average by robotic system automatically. An average of 30 min was saved compared with the manual positioning procedure in phantom experiments. This paper describes the design and experimental validation of a novel CT-guided robotic system for lung cancer brachytherapy. The robotic system was validated in a number of aspects which prove that it was capable of locating the template with clinically acceptable accuracy in the CT environment. All experimental results indicated that the system is reliable and ready to be applied to further studies on animals.

Dosimetric study of 3D-printing coplanar template combined with CT-guided 125I seed implantation for treating non-small cell lung cancer

Objective To explore the safety, effectivity and dosimetric continence of 3D-printing coplanar template(3D-PCT)combined with CT-guided 125I seed implantation in the treatment of non-small cell lung cancer(NSCLC). Methods From May 2014 to November 2016, a total of 20 NSCLC patients who were suitable for 125I seed implantation were recruited in this study. Of all the patients, 10 received 125I seed implantation treatment by CT-guided combined with 3D-PCT (3D group), and the rest, by free-hand puncture combined with CT-guided 125I seed implantation (free-hand group). During two days before the surgery, the patients received the CT scan. Then the digital imaging and communications in medicine(DICOM) was collected to input to the Brachytherapy Treatment Planning System(BTPS). The dose parameters including D90, D100, V100, V150, conformal index(CI), external index(EI), and homogneneity index(HI) were compared between pre-operation and post-operation. Pair t-test and single sample t-test were performed. Results V150 in 3D group between preoperation and postoperation showed statistically significant difference(t=-2.916, P 0.05). However, the number of seeds, V100, EI, HI in free-hand group between preoperation and postoperation showed statistically significant difference(t=-2.516, 2.492, 4.725, 7.258, P 0.05). Comparison of indicuted that there was significant difference in V100, V150, CI, EI, HI and dose error rate between the 3D group and the free-hand group with single sample t test, the result showed V100, CI, EI, HI between two groups(t=2.598, 2.278, 4.637, 4.616, -4.785, P 0.05). Conclusions CT-guided 125I seed implantation brachytherapy combined with 3D-PCT for treatment of NSCLC safe is feasible, and dose controllable, and there is a certain advantage in the spatial distribution of seed compared with free-hand puncture. Key words: 3D-printing; Coplanar template; Free hand; 125I seed implantation; Non small cell lung cancer

Automated construction of an intraoperative high-dose-rate treatment plan library for the Varian brachytherapy treatment planning system

PurposeThe ability to create treatment plans for intraoperative high-dose-rate (IOHDR) brachytherapy is limited by lack of imaging and time constraints. An automated method for creation of a library of high-dose-rate brachytherapy plans that can be used with standard planar applicators in the intraoperative setting is highly desirable. Methods and MaterialsNonnegative least squares algebraic methods were used to identify dwell time values for flat, rectangular planar applicators. The planar applicators ranged in length and width from 2 cm to 25 cm. Plans were optimized to deliver an absorbed dose of 10 Gy to three different depths from the patient surface: 0 cm, 0.5 cm, and 1.0 cm. Software was written to calculate the optimized dwell times and insert dwell times and positions into a .XML plan template that can be imported into the Varian brachytherapy treatment planning system. The user may import the .XML template into the treatment planning system in the intraoperative setting to match the patient applicator size and prescribed treatment depth. ResultsA total of 1587 library plans were created for IOHDR brachytherapy. Median plan generation time was approximately 1 minute per plan. Plan dose was typically 100% ± 1% (mean, standard deviation) of the prescribed dose over the entire length and width of the applicator. Plan uniformity was best for prescription depths of 0 cm and 0.5 cm from the patient surface. ConclusionsAn IOHDR plan library may be created using automated methods. Thousands of plan templates may be optimized and prepared in a few hours to accommodate different applicator sizes and treatment depths and reduce treatment planning time. The automated method also enforces dwell time symmetry for symmetrical applicator geometries, which simplifies quality assurance.

Imaging-Based Surgical Navigated 125i Interstitial Brachytherapy for Locally Advanced Salivery Gland Carcinoma

The precise placement of the needles and seeds is mandatory in interstitial brachytherapy. This study is to explore the practice of accurate positioning of imaging-based surgical navigated 125i interstitial brachytherapy for treatment of locally advanced salivery gland carcinoma. Seventeen patients with locally advanced salivery gland carcinoma were included in this retrospective study. Before 125I implants, the implantation plan was made through the brachytherapy treatment planning system software based on patient’s CT. The template was designed by using Mimics and Geomagic software based on the implantation plan and made through rapid prototyping technique. The template data in STL format and CT were imported into the iPlan CMF software, merged into one object according to the 3-D appearance of the skin and became the navigation plan, which was transferred to the VectorVision navigation system before implantation. During the implantation, the template was placed to the planned position by the guidance of the navigation plan. The needles were implanted using the template and navigation plan guidance, to ensure that all needles were in the expected position and depth. After implants, treatment quality evaluation was made by TPS based on the post-implantation CT. The implantations of all patients were performed sucessfully under navigation plan guidance. The seeds and dosages distribution (D90,V100,V150) were well meet the treatment requirement. The navigation system will be a very useful clinical tool for interstitial brachytherapy applications. Clinical practice confirms that this approach can facilitate easier and more accurate implantation.

Verification of Oncentra brachytherapy planning using independent calculation

This study was done to investigate the verification technique of treatment plan quality assurance for brachytherapy. It is aimed to verify the point doses in 192Ir high dose rate (HDR) brachytherapy between Oncentra Masterplan brachytherapy treatment planning system and independent calculation software at a region of rectum, bladder and prescription points for both pair ovoids and full catheter set ups. The Oncentra TPS output text files were automatically loaded into the verification programme that has been developed based on spreadsheets. The output consists of source coordinates, desired calculation point coordinates and the dwell time of a patient plan. The source strength and reference dates were entered into the programme and then dose point calculations were independently performed. The programme shows its results in a comparison of its calculated point doses with the corresponding Oncentra TPS outcome. From the total of 40 clinical cases that consisted of two fractions for 20 patients, the results that were given in term of percentage difference, it shows an agreement between TPS and independent calculation are in the range of 2%. This programme only takes a few minutes to be used is preferably recommended to be implemented as the verification technique in clinical brachytherapy dosimetry.

Commissioning of an ultrasound based HDR brachytherapy treatment planning system

Commissioning of an ultrasound based HDR brachytherapy treatment planning system

English

Conventional two-dimensional (2D) treatment planning of intracavitary brachytherapy is still a common practice at the radiotherapy center. The purpose of this study was to evaluate the organ at risk (OAR) doses estimated based on International Commission on Radiation Units and Measurements (ICRU) reference-point in patients with cervical cancer treated with high-dose-rate (HDR) intracavitary brachytherapy (ICBT). Between January 2010 and April 2014, 21 cervical cancer patients were treated with 42 fractions of brachytherapy using tandem and ovoids and underwent post-implant two-dimensional (2D) radiograph scans. HDR brachytherapy was delivered to a dose of 18 Gy in two fractions. Using the Oncentra brachytherapy treatment planning system (BTPS) software version 4.1 (Nucletron, Netherlands), the bladder and rectum points were retrospectively reconstructed based on 42 orthogonal radiographs datasets. The ICRU bladder and rectum point doses were recorded. As for results, the mean percentage dose of rectum and bladder for selected patients treated with intracavitary brachytherapy treatment (ICBT) were 47.27 and 75.59%, respectively. Combinations of ovoid’s size, length of tandem and anatomy variation between each patient were factors that affected the dose to the OAR. Therefore, the ICRU reference points can still be used with the 2D brachytherapy treatment planning in evaluating the OAR doses.

Brachytherapy treatment planning commissioning: effect of the election of proper bibliography and finite size of TG-43 input data on standard treatments.

The aim of this work is to evaluate the performance of a commercial brachytherapy treatment planning system (TPS) with TG‐43 Vendors Input Data (VID), analyze possible discrepancies with respect to a proper reference source and its implications for standard treatments, and judge the effectiveness of certain widespread recommended quality controls to find potential errors related with the interpolations of TG‐43 VID tables. The TPS evaluated was a BrachyVision 8.6 loaded with TG‐43 VID for a VariSource high‐dose‐rate 192Ir source (Vs2000). The reference data chosen were the TG‐43 data published in the literature. In the first step, we compared TG‐43 VID with respect to the chosen reference data. Next, we used percent dose‐rate differences in a point array matrix to compare the outcomes of the TPS on standard treatment setup with respect to an in‐house developed program (MATLAB R2009a‐based) loaded with the chosen full TG‐43 reference data. The cases with major discrepancies were evaluated using the gamma‐index analysis. The comparison with the reference data indicated a lack of sample in the angles between near to the tip (between 165<θ<180) and cable (0<θ<15) of the F(r,θ)VID, which causes a dose underestimation of approximately 17% in the investigated points due to inaccurate interpolations. The differences over 2% encompassed approximately 17% of the surrounding source volume. These results have special relevance in treatment using one applicator with a few dwell steps or in Fletcher treatments where 10% dose underestimates were identified within the tumor or in organs at risk, respectively. Our results suggest that the differences found in the TPS under study are created by a lack of information on the angles in high‐gradient zones in the F(r,θ)VID, which generates important differences in dosimetric results. In contrast, the gamma analysis shows very good results (between 90% and 100% of passed points) in the analyzed treatments (one dwell and Fletcher). Further studies are required to exclude the possibility of finding noticeable effects in the DVH of treatment plans caused by the discrepancies here described. To achieve more strict control over the TPS dose‐rate calculation, we recommend using QA test thinking in a source with nonaxial symmetry, adding a control point on the angles of the high‐dose gradient zones (e.g., between 0° and 15° and between 165° and 180°). More studies are required to achieve full understanding of the clinical implication of such discrepancies.PACS number: 87.55.Qr

A feasibility study for using ABS plastic and a low-cost 3D printer for patient-specific brachytherapy mould design

This feasibility study aims to determine if a low-cost 3D printer (BitsFromBytes 3D Touch) with ABS plastic can print custom mould structures and catheter channels defined in a brachytherapy treatment planning system (Nucletron Oncentra) for patient-specific treatment. Printer accuracy was evaluated through physical measurement, and print quality was investigated by adjusting print parameters (print speed, layer thickness, percentage infill). Catheter positioning and reproducibility were measured over repeated insertions. ABS plastic water equivalency was investigated by comparing Ir-192 HDR source dose distributions, measured with radiochromic film, in ABS plastic and in water. Structures and catheter channels were printed accurately to within 0.5mm laterally and 1mm in the vertical print direction. Adjusting print parameters could reduce print time, albeit with reduced print quality. 3.5mm channel diameters allowed for easy catheter insertion. Catheter positioning was reproducible to within 0.5mm but, because of catheter flex within the channel, was on average 1mm offset from defined TPS positions. This offset could be accounted for by repeating the treatment planning CT scan with the printed mould positioned on the patient. Dose attenuation in ABS plastic and in water was equivalent to within the measurement limitations. While clinical uses for this particular low-cost printer and ABS plastic are limited by print size restrictions and non-certification for biocompatibility, it has been demonstrated that a low-cost 3D printer set-up can accurately create custom moulds and catheter channels potentially acceptable for clinical use.

SU‐E‐J‐166: Sensitivity of Clinically Relevant Dosimetric Parameters to Contouring Uncertainty During Post Implant Dosimetry of Prostate Permanent Seed Implants

Purpose:There is a strong evidence relating post‐implant dosimetry for permanent seed prostate brachytherpy to local control rates. The delineation of the prostate on CT images, however, represents a challenge as it is difficult to confidently identify the prostate borders from soft tissue surrounding it. This study aims at quantifying the sensitivity of clinically relevant dosimetric parameters to prostate contouring uncertainty.Methods:The post‐implant CT images and plans for a cohort of 43 patients, who have received I–125 permanent prostate seed implant in our centre, were exported to MIM Symphony LDR brachytherapy treatment planning system (MIM Software Inc., Cleveland, OH). The prostate contours in post‐implant CT images were expanded/contracted uniformly for margins of ±1.00mm, ±2.00mm, ±3.00mm, ±4.00mm and ±5.00mm (±0.01mm). The values for V100 and D90 were extracted from Dose Volume Histograms for each contour and compared.Results:The mean value of V100 and D90 was obtained as 92.3±8.4% and 108.4±12.3% respectively (Rx=145Gy). V100 was reduced by −3.2±1.5%, −7.2±3.0%, −12.8±4.0%, −19.0±4.8%, − 25.5±5.4% for expanded contours of prostate with margins of +1mm, +2mm, +3mm, +4mm, and +5mm, respectively, while it was increased by 1.6±1.2%, 2.4±2.4%, 2.7±3.2%, 2.9±4.2%, 2.9±5.1% for the contracted contours. D90 was reduced by −6.9±3.5%, −14.5±6.1%, −23.8±7.1%, − 33.6±8.5%, −40.6±8.7% and increased by 4.1±2.6%, 6.1±5.0%, 7.2±5.7%, 8.1±7.3% and 8.1±7.3% for the same set of contours.Conclusion:Systematic expansion errors of more than 1mm may likely render a plan sub‐optimal. Conversely contraction errors may Result in labeling a plan likely as optimal. The use of MRI images to contour the prostate should results in better delineation of prostate organ which increases the predictive value of post‐op plans. Since observers tend to overestimate the prostate volume on CT, compared with MRI, the impact of the contouring uncertainty on V100 and D90 fortunately, has a conservative effect of underestimating the prostate coverage.

Comparison of Oncentra® Brachy IPSA and graphical optimisation techniques: a case study of HDR brachytherapy head and neck and prostate plans.

There are a number of different dwell positions and time optimisation options available in the Oncentra® Brachy (Elekta Brachytherapy Solutions, Veenendaal, The Netherlands) brachytherapy treatment planning system. The purpose of this case study was to compare graphical (GRO) and inverse planning by simulated annealing (IPSA) optimisation techniques for interstitial head and neck (HN) and prostate plans considering dosimetry, modelled radiobiology outcome and planning time. Four retrospective brachytherapy patients were chosen for this study, two recurrent HN and two prostatic boosts. Manual GRO and IPSA plans were generated for each patient. Plans were compared using dose–volume histograms (DVH) and dose coverage metrics including; conformity index (CI), homogeneity index (HI) and conformity number (CN). Logit and relative seriality models were used to calculate tumour control probability (TCP) and normal tissue complication probability (NTCP). Approximate planning time was also recorded. There was no significant difference between GRO and IPSA in terms of dose metrics with mean CI of 1.30 and 1.57 (P > 0.05) respectively. IPSA achieved an average HN TCP of 0.32 versus 0.12 for GRO while for prostate there was no significant difference. Mean GRO planning times were greater than 75 min while average IPSA planning times were less than 10 min. Planning times for IPSA were greatly reduced compared to GRO and plans were dosimetrically similar. For this reason, IPSA makes for a useful planning tool in HN and prostate brachytherapy.

3D Printing Individual Templates Guided Brachytherapy in Head and Neck

3D Printing Individual Templates Guided Brachytherapy in Head and Neck

The influence of the dwell time deviation constraint (DTDC) parameter on dosimetry with IPSA optimisation for HDR prostate brachytherapy.

To investigate how the dwell time deviation constraint (DTDC) parameter, applied to inverse planning by simulated annealing (IPSA) optimisation limits large dwell times from occurring in each catheter and to characterise the effect on the resulting dosimetry for prostate high dose rate (HDR) brachytherapy treatment plans. An unconstrained IPSA optimised treatment plan, using the Oncentra Brachytherapy treatment planning system (version 4.3, Nucletron an Elekta company, Elekta AB, Stockholm, Sweden), was generated for 20 consecutive HDR prostate brachytherapy patients, with the DTDC set to zero. Successive constrained optimisation plans were also created for each patient by increasing the DTDC parameter by 0.2, up to a maximum value of 1.0. We defined a "plan modulation index", to characterise the change of dwell time modulation as the DTDC parameter was increased. We calculated the dose volume histogram indices for the PTV (D90, V100, V150, V200%) and urethra (D10%) to characterise the effect on the resulting dosimetry. The average PTV D90% decreases as the DTDC is applied, on average by only 1.5 %, for a DTDC = 0.4. The measures of high dose regions in the PTV, V150 and V200%, increase on average by less than 5 and 2 % respectively. The net effect of DTDC on the modulation of dwell times has been characterised by the introduction of the plan modulation index. DTDC applied during IPSA optimisation of HDR prostate brachytherapy plans reduce the occurrence of large isolated dwell times within individual catheters. The mechanism by which DTDC works has been described and its effect on the modulation of dwell times has been characterised. The authors recommend using a DTDC parameter no greater than 0.4 to obtain a plan with dwell time modulation comparable to a geometric optimised plan. This yielded on average a 1.5 % decrease in PTV coverage and an acceptable increase in V150%, without compromising the urethral dose.

A 3D computer-assisted treatment planning system for breast cancer brachytherapy treatment.

Purpose Brachytherapy is an option for treatment of breast cancer in some cases. This modality requires patient-specific dosimetry based on CT simulator scans. A 3D computer-assisted breast brachytherapy treatment planning system called Vision was developed and tested.Methods The brachytherapy treatment planning system used volume estimation and dose analysis with advanced 3D visualization. The patient treatment volume reconstruction was designed to ensure high-volume accuracy requirement of radioactive seed implantation procedure for this treatment. The system enables interactive placement of radioactive seeds embedded in original patient CT images with 3D display.Results The system achieved 99.73 % accuracy in volume estimation measured against the true volume and is statistically significantly more accurate than current existing commercial software at the p=0.05 level.Conclusion A virtual 3D environment was developed to perform volume measurements, seed placements, and dose distribution planning and analysis based on 2D contours on patient CT images. This system was demonstrated to be feasible and accurate in a clinical setting.

A Novel Algorithm Accounting for Inter-Seed Attenuation Effect in Brachytherapy Treatment Planning Systems by Monte Carlo and Artificial Neural Networks

A Novel Algorithm Accounting for Inter-Seed Attenuation Effect in Brachytherapy Treatment Planning Systems by Monte Carlo and Artificial Neural Networks

Brachytherapy in cancer cervix: Time to move ahead from point A?

Brachytherapy forms an integral part of the radiation therapy in cancer cervix. The dose prescription for intracavitary brachytherapy (ICBT) in cancer cervix is based on Tod and Meredith's point A and has been in practice since 1938. This was proposed at a time when accessibility to imaging technology and dose computation facilities was limited. The concept has been in practice worldwide for more than half a century and has been the fulcrum of all ICBT treatments, strategies and outcome measures. The method is simple and can be adapted by all centres practicing ICBT in cancer cervix. However, with the widespread availability of imaging techniques, clinical use of different dose-rates, availability of a host of applicators fabricated with image compatible materials, radiobiological implications of dose equivalence and its impact on tumour and organs at risk; more and more weight is being laid down on individualised image based brachytherapy. Thus, computed tomography, magnetic-resonance imaging and even positron emission computerized tomography along with brachytherapy treatment planning system are being increasingly adopted with promising outcomes. The present article reviews the evolution of dose prescription concepts in ICBT in cancer cervix and brings forward the need for image based brachytherapy to evaluate clinical outcomes. As is evident, a gradual transition from "point" based brachytherapy to "profile" based image guided brachytherapy is gaining widespread acceptance for dose prescription, reporting and outcome evaluation in the clinical practice of ICBT in cancer cervix.

I‐125 ROPES eye plaque dosimetry: Validation of a commercial 3D ophthalmic brachytherapy treatment planning system and independent dose calculation software with GafChromic® EBT3 films

The purpose of this study was to measure the dose distributions for different Radiation Oncology Physics and Engineering Services, Australia (ROPES) type eye plaques loaded with I-125 (model 6711) seeds using GafChromic(®) EBT3 films, in order to verify the dose distributions in the Plaque Simulator™ (PS) ophthalmic 3D treatment planning system. The brachytherapy module of RADCALC(®) was used to independently check the dose distributions calculated by PS. Correction factors were derived from the measured data to be used in PS to account for the effect of the stainless steel ROPES plaque backing on the 3D dose distribution. Using GafChromic(®) EBT3 films inserted in a specially designed Solid Water™ eye ball phantom, dose distributions were measured three-dimensionally both along and perpendicular to I-125 (model 6711) loaded ROPES eye plaque's central axis (CAX) with 2 mm depth increments. Each measurement was performed in full scatter conditions both with and without the stainless steel plaque backing attached to the eye plaque, to assess its effect on the dose distributions. Results were compared to the dose distributions calculated by Plaque Simulator™ and checked independently with RADCALC(®). The EBT3 film measurements without the stainless steel backing were found to agree with PS and RADCALC(®) to within 2% and 4%, respectively, on the plaque CAX. Also, RADCALC(®) was found to agree with PS to within 2%. The CAX depth doses measured using EBT3 film with the stainless steel backing were observed to result in a 4% decrease relative to when the backing was not present. Within experimental uncertainty, the 4% decrease was found to be constant with depth and independent of plaque size. Using a constant dose correction factor of T = 0.96 in PS, where the calculated dose for the full water scattering medium is reduced by 4% in every voxel in the dose grid, the effect of the plaque backing was accurately modeled in the planning system. Off-axis profiles were also modeled in PS by taking into account the three-dimensional model of the plaque backing. The doses calculated by PS and RADCALC(®) for uniformly loaded ROPES plaques in full and uniform scattering conditions were validated by the EBT3 film measurements. The stainless steel plaque backing was observed to decrease the measured dose by 4%. Through the introduction of a scalar correction factor (0.96) in PS, the dose homogeneity effect of the stainless steel plaque backing was found to agree with the measured EBT3 film measurements.

A BrachyPhantom for verification of dose calculation of HDR brachytherapy planning system

To develop a calibration phantom for (192)Ir high dose rate (HDR) brachytherapy units that renders possible the direct measurement of absorbed dose to water and verification of treatment planning system. A phantom, herein designated BrachyPhantom, consists of a Solid Water™ 8-cm high cylinder with a diameter of 14 cm cavity in its axis that allows the positioning of an A1SL ionization chamber with its reference measuring point at the midheight of the cylinder's axis. Inside the BrachyPhantom, at a 3-cm radial distance from the chamber's reference measuring point, there is a circular channel connected to a cylindrical-guide cavity that allows the insertion of a 6-French flexible plastic catheter from the BrachyPhantom surface. The PENELOPE Monte Carlo code was used to calculate a factor, P(sw)(lw), to correct the reading of the ionization chamber to a full scatter condition in liquid water. The verification of dose calculation of a HDR brachytherapy treatment planning system was performed by inserting a catheter with a dummy source in the phantom channel and scanning it with a CT. The CT scan was then transferred to the HDR computer program in which a multiple treatment plan was programmed to deliver a total dose of 150 cGy to the ionization chamber. The instrument reading was then converted to absorbed dose to water using the N(gas) formalism and the P(sw)(lw) factor. Likewise, the absorbed dose to water was calculated using the source strength, Sk, values provided by 15 institutions visited in this work. A value of 1.020 (0.09%, k = 2) was found for P(sw)(lw). The expanded uncertainty in the absorbed dose assessed with the BrachyPhantom was found to be 2.12% (k = 1). To an associated Sk of 27.8 cGy m(2) h(-1), the total irradiation time to deliver 150 cGy to the ionization chamber point of reference was 161.0 s. The deviation between the absorbed doses to water assessed with the BrachyPhantom and those calculated by the treatment plans and using the Sk values did not exceed ± 3% and ± 1.6%, respectively. The BrachyPhantom may be conveniently used for quality assurance and/or verification of HDR planning system with a priori threshold level to spot problems of 2% and ± 3%, respectively, and in the long run save time for the medical physicist.